A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea

StatusRecruiting
PhaseNot specified
SponsorTakeda
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Trial sites expanded: 0 → 3 locations
    • Start date changed from estimate of Oct 1, 2026 to Sep 21, 2026
    • Eligibility criteria expanded, about 5 words
  2. Start date: Jul 1, 2026 to Oct 1, 2026v4
  3. Start date: May 1, 2026 to Jul 1, 2026v3
  4. Re-verified, no change to tracked fieldsv2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Takeda
222 trials monitored
See 14 trials at risk
Takhzyro is an approved treatment for hereditary angioedema (HAE) in South Korea. HAE is a rare condition which causes sudden swelling under the skin and inside the body, like in the belly, throat, or genitals. The main aim of this study is to check how safe Takhzyro is in teenagers and adults with HAE in everyday medical care in South Korea. Another aim is to see how well Takhzyro works in everyday medical care. The treatment of participants and any check-ups will be determined by the treating doctors according to their normal practice. Participants may visit the study clinic several times during the study.
Trial Details
NCT Number NCT07445087
Lead Sponsor Takeda
Conditions
(from sponsor)		 Hereditary Angioedema (HAE)
Related terms Angioedemas, Hereditary
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov